Instead, combination therapy with rapamycin and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), led to reduced tumor sizes as well as prolonged survival in xenograft mice. Here, VEGFA is linked to neoplasm.